Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2023-04-14 | 2023-06-08 | 189659 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2021-07-09 | 2022-10-07 | 142272 |
| APO-DABIGATRAN | 150MG | CAPSULE | Resolved | 2020-08-19 | 2021-01-26 | 122473 |
| APO-DABIGATRAN | 110MG | CAPSULE | Actual shortage | 2024-11-15 | 2024-11-15 | 243170 |
| APO-DABIGATRAN | 110MG | CAPSULE | Resolved | 2024-12-05 | 2025-01-24 | 244888 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2024-03-08 | 2024-04-19 | 221678 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-09-01 | 2024-01-05 | 203563 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-11-06 | 2024-01-05 | 209333 |
| APO-DAPAGLIFLOZIN | 10MG | TABLET | Resolved | 2023-10-27 | 2024-01-05 | 208370 |
| APO-DAPAGLIFLOZIN-METFORMIN | 850MG 5MG | TABLET | Resolved | 2024-12-05 | 2024-12-13 | 244918 |
| APO-DAPAGLIFLOZIN-METFORMIN | 1000MG 5MG | TABLET | Resolved | 2024-06-20 | 2024-08-02 | 231020 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-14 | 2022-02-03 | 152758 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-10-01 | 2022-01-24 | 146503 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-01 | 2024-07-05 | 212368 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-10-11 | 213547 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2020-06-04 | 2020-06-26 | 116530 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2024-06-06 | 2024-10-07 | 229752 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2022-10-21 | 2022-12-17 | 172360 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2024-09-12 | 2024-09-20 | 237354 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |